Acute myeloid leukemias (AML) are a group of aggressive hematologic malignancies resulting from acquired genetic mutations in hematopoietic stem cells that affect patients of all ages. Despite decades of research, standard chemotherapy still remains ineffective for some AML subtypes and is often inappropriate for older patients or those with comorbidities. Recently, a number of studies have identified unique mitochondrial alterations that lead to metabolic vulnerabilities in AML cells that may present viable treatment targets. These include mtDNA, dependency on oxidative phosphorylation, mitochondrial metabolism, and pro-survival signaling, as well as reactive oxygen species generation and mitochondrial dynamics. Moreover, some mitochondria-targeting chemotherapeutics and their combinations with other compounds have been FDA-approved for AML treatment. Here, we review recent studies that illuminate the effects of drugs and synergistic drug combinations that target diverse biomolecules and metabolic pathways related to mitochondria and their promise in experimental studies, clinical trials, and existing chemotherapeutic regimens.

中文翻译：

---

线粒体代谢作为急性髓细胞白血病的治疗靶点

急性髓细胞性白血病（AML）是一组侵袭性血液恶性肿瘤，这些恶性肿瘤是由造血干细胞中获得性遗传突变引起的，影响了各个年龄段的患者。尽管进行了数十年的研究，标准化学疗法对于某些AML亚型仍然无效，并且通常不适用于老年患者或合并症患者。最近，许多研究发现了独特的线粒体改变，这些改变会导致AML细胞中的代谢脆弱性，从而可能提出可行的治疗靶标。这些包括mtDNA，对氧化磷酸化的依赖，线粒体代谢和促存活信号，以及活性氧的产生和线粒体动力学。而且，某些针对线粒体的化学疗法及其与其他化合物的组合已被FDA批准用于AML治疗。在这里，我们回顾了最近的研究，这些研究阐明了针对线粒体相关的多种生物分子和代谢途径的药物和协同药物组合的作用，以及它们在实验研究，临床试验和现有化疗方案中的前景。